Delivery Order SPE2DR25D1109-SPE2DR26FFF8E
- Not listed
- The Defense Logistics Agency awarded a $41,480.93 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Rexulti 1 mg tablets (30-count units). This firm fixed-price, competitively awarded contract with an ultimate completion date of July 29, 2025, represents a child order under AmerisourceBergen's larger pharmaceutical supply vehicle with the DLA. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order valued at $2,417.22 to AmerisourceBergen Drug Corp for Rexulti 2 mg tablets (30-count package) on September 25, 2025, with an ultimate completion date of September 26, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a single delivery order under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $11,740.62 to AmerisourceBergen Drug Corp for the supply of Rexulti (brexpiprazole) 1 mg tablets in a 30-count package. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and carries an ultimate completion date of October 31, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Rexulti 2 mg tablets (quantity: 30 units) with a ceiling value of $2,927.61. This firm fixed-price delivery order, which was competitively awarded with no set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026....
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $6,239.25 by the Defense Logistics Agency on October 24, 2025, for the supply of Rexulti 3 mg tablets (30-count packaging). This firm fixed-price, competitively awarded delivery order is scheduled for completion by October 27, 2025, with performance taking place at the company's Conshohocken facility. The award represents a child contract under...
- The Defense Logistics Agency awarded a $5,123.39 delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of Rexulti 1 mg tablets (30-count units). The contract, which is a firm fixed price delivery order with no set-aside designation, is scheduled for completion by September 22, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 30, 2025, for the supply of Rexulti 1 mg tablets (30-count packaging) with a contract value of $1,640.36. This is a firm fixed price delivery order with an ultimate completion date of October 31, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement...
- The Defense Logistics Agency awarded a delivery order valued at $30,339.39 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count units) under a firm fixed price arrangement. The award, issued on July 29, 2025, with an ultimate completion date of July 30, 2025, represents a non-competitive delivery order placed against AmerisourceBergen's larger contract vehicle. Performance will be executed at the contractor's facility in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Rexulti 2 mg tablets (30-count packages) with a ceiling value of $9,967.07. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 8, 2025, and will be fulfilled from AmerisourceBergen's operations in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating open competition among qualified...
- The Defense Logistics Agency awarded a delivery order valued at $2,846.60 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count package). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of September 24, 2025. The award was issued on September 23, 2025, with performance to be fulfilled at AmerisourceBergen's Conshohocken, Pennsylvania facility. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- SPE2DR25D1109Indefinite Delivery Contract
- SPE2DR25D1109-SPE2DR26FFF8EDelivery Order
The Defense Logistics Agency awarded a $9,480.14 delivery order to AmerisourceBergen Drug Corp for 30 tablets of Rexulti 2 mg on October 30, 2025, with completion scheduled for October 31, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the prime contractor. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 global pharmaceutical support vehicle running through December 2026 that enables the company to supply pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal medical procurement, particularly for military and veteran healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to supply a comprehensive range of products including brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. Rexulti (brexpiprazole), an atypical antipsychotic medication, is consistent with the company's track record of delivering neurological and psychiatric treatments through the DLA Medical Supply Chain to support the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.5k | 10/30/25 |